ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Pharmacokinetic insights into atezolizumab SC: viability of extended dosing intervals beyond the standard regimen.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAtezolizumab is a monoclonal antibody against programmed cell death ligand 1 (PD-L1) used in oncology. With the intravenous formulation, the standard dose exceeds the established minimum effective concentration (MEC, 6 μg/mL). A subcutaneous (SC) triweekly formulation was recently introduced. This study aimed to predict SC atezolizumab exposure under extended dosing regimens using a population pharmacokinetic (PopPK) model.
methodsThis study used a PopPK in silico model based on data from the IMscin001 trial (SC atezolizumab in non-small cell lung cancer) to predict exposure for SC atezolizumab 1875 mg administered every 4, 5, 6, and 7 weeks (q4w-q7w). Simulations were performed in Monolix. Minimum concentrations after the first cycle (C
resultsThe model showed good agreement between simulated and observed plasma concentrations (PC), supporting its predictive performance. With q4w, C
conclusionsOur PopPK model suggests that extending SC atezolizumab dosing to 4 or 5 weeks maintains therapeutic efficacy and could serve as a clinically viable alternative to standard triweekly dosing. Longer intervals may reduce efficacy and require clinical validation.
Indexed as
Identifiers
41790429What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.